Neumora Therapeutics
NMRA
134 hedge funds and large institutions have $852M invested in Neumora Therapeutics in 2024 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 39 increasing their positions, 31 reducing their positions, and 14 closing their positions.
214% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 14
29% more funds holding
Funds holding: 104 → 134 (+30)
26% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 31
6.81% more ownership
Funds ownership: 42.92% → 49.72% (+6.8%)
4% more call options, than puts
Call options by funds: $64.8M | Put options by funds: $62.2M
6% less capital invested
Capital invested by funds: $907M → $852M (-$55.4M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$41.1M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$38.7M |
| 3 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$21.4M |
| 4 |
JP Morgan Chase
New York
|
+$16M |
| 5 |
BlackRock
New York
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$21.6M |
| 2 |
SoftBank Group
Tokyo,
Japan
|
-$12.1M |
| 3 |
IC
Iconiq Capital
San Francisco,
California
|
-$10.1M |
| 4 |
O
OrbiMed
New York
|
-$8.33M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.11M |
NMRA Hedge Fund Activity: Q4 2024 in Review
134 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q4 2024, worth a combined $852M — down 6.1% from $907M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new NMRA positions and 14 closed out — a net gain of 30 holders — while 39 added to existing stakes and 31 trimmed.
The largest buyer was Deep Track Capital, adding an estimated $41.1M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $21.6M sold.
- 134 institutional investors held Neumora Therapeutics (NMRA) as of Q4 2024, up from 104 in Q3 2024.
- Funds reported $852M of Neumora Therapeutics stock for Q4 2024, down 6.1% quarter-over-quarter.
- 44 funds opened new Neumora Therapeutics positions in Q4 2024 and 14 closed out, a net change of +30 holders.
- The largest Neumora Therapeutics buyer in Q4 2024 was Deep Track Capital, an estimated $41.1M added.
- The largest Neumora Therapeutics seller in Q4 2024 was Avidity Partners Management, an estimated $21.6M sold.
Based on aggregated 13F filings for Q4 2024.